SCHEMBL177501

SCHEMBL177501

Clc1ccc(OBOc2ccc(Cl)c(Cl)c2)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.47
SLC6A4 P31645 4/20 0.44
SLC6A2 P23975 2/20 0.44
SLC6A3 Q01959 2/20 0.44
AHR P35869 1/20 0.42
TP53 P04637 1/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HAO1 Q9UJM8 1/20 0.40
KMO O15229 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
APEX1 P27695 1/20 0.37
HTR2A P28223 3/20 0.36
KCNH2 Q12809 3/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17429154 0.81 HSP90AA1 (0.48) HSP90AA1SLC6A4SLC6A2SLC6A3AHR
SCHEMBL177406 0.79 MCL1 (0.49) SLC6A4TP53MEN1KMT2AKDM4E
SCHEMBL522748 0.79 PPARG (0.41) SLC6A4SLC6A2SLC6A3KMT2ACYP3A4
SCHEMBL3540409 0.79 TSHR (0.48) TP53MEN1KMT2AKDM4ECYP3A4
SCHEMBL522666 0.79 SOS1 (0.46) SLC6A4MEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL529160 0.79 HSD17B10 (0.48) HSP90AA1CYP3A4TSHRHSD17B10SMN1; SMN2
SCHEMBL177455 0.79 CYP3A4 (0.45) SLC6A4SLC6A2SLC6A3MEN1KMT2A
SCHEMBL177471 0.76 CA12 (0.43) SLC6A4SLC6A2SLC6A3MEN1KMT2A
SCHEMBL15521889 0.76 CA12 (0.43) SLC6A4MEN1KMT2ACYP3A4TSHR
SCHEMBL21820786 0.76 HSP90AA1 (0.71) HSP90AA1SLC6A4SLC6A2SLC6A3AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 US disclosed
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INST NAT SANTE RECH MED (FR) 2025-12-18 US disclosed
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 US disclosed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 EP disclosed
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2025-01-30 US disclosed
CN-118176183-A HIF-2 alpha inhibitors and methods of use thereof 艾库斯生物科学有限公司 2024-06-11 CN disclosed
US-11964944-B2 Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases THE UNIVERSITY OF CHICAGO (US) 2024-04-23 US disclosed
US-11958854-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, LLC (US) 2024-04-16 US disclosed
CN-117794915-A Compound, material for organic electroluminescent device comprising the same, and organic electroluminescent device 出光兴产株式会社 2024-03-29 CN disclosed
CN-114072207-B Bicyclic compounds 维瓦斯治疗公司 2024-03-29 CN disclosed
US-5948933-A THERAPY FOR DRUG ABRUSE ORGANIX, INC. (US) 1999-09-07 US disclosed
WO-1999002526-A1 TROPANE ANALOGS AND METHODS FOR INHIBITION OF MONOAMINE TRANSPORT ORGANIX, INC. (US) 1999-01-21 WO disclosed
EP-0691966-B1 QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS SYNTEX INC (US) 1998-09-09 EP disclosed
US-5770180-A COCAINE ORGANIX, INC. (US) 1998-06-23 US disclosed
WO-1997040859-A1 BRIDGE-SUBSTITUTED TROPANES AND USES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1997-11-06 WO disclosed
US-5530005-A THERAPY FOR SKIN DISORDERS, AIDS, IMMUNOSUPPRESION DISEASES SYNTEX (U.S.A.) INC. (US) 1996-06-25 US disclosed
EP-0691966-A1 QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-01-17 EP disclosed
US-5475003-A Antiinflammatory agent, immunosuppressive, antiallergens, bronchodilators, analgens SYNTEX (U.S.A.) INC. (US) 1995-12-12 US disclosed
US-5455252-A Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic SYNTEX (U.S.A.) INC. (US) 1995-10-03 US disclosed
WO-1994022852-A1 QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1994-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SCNN1B, SCN1B, SCN2B HSP90AA1 2857/4885SLC6A4 146/4885SLC6A2 51/4885
US-11964944-B2 Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases TUBB1, MYADM, TUBB HSP90AA1 117/4885SLC6A4 4295/4885SLC6A2 4381/4885
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS BBOX1, NDUFB6, NDUFB5 HSP90AA1 493/4885SLC6A4 2397/4885SLC6A2 1976/4885
US-11958854-B2 Substituted xanthines and methods of use thereof TRPC5, TRPC7, TRPC4 HSP90AA1 3910/4885SLC6A4 78/4885SLC6A2 121/4885
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 HSP90AA1 3910/4885SLC6A4 78/4885SLC6A2 121/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 HSP90AA1 1032/4885SLC6A4 766/4885SLC6A2 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.